Skip to content

Comparing the 3 months benefits of topical and oral use of Coenzyme Q10 in treating chronic periodontitis patients

Clinical Evaluation of Effects of Adjunctive Use of Topical and Systemic Administration of Coenzyme Q10 in Non- Surgical Periodontal Therapy: A Randomized Controlled Trial. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/12/098502
Enrollment
69
Registered
2025-12-04
Start date
Unknown
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K053- Chronic periodontitis

Interventions

Intervention1: Coenzyme Q10 as local irrigation, oral administration and dentifrice with scaling and root planing in stage II periodontitis patients: Scaling, polishing and root planing will be perfor

Sponsors

Anisha Rani
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. patients diagnosed with stage II periodontitis 2. having more than two non-adjacent sites with probing pocket depth (PPD) of more than or equal to 4mm and less than or equal to 5mm and clinical attachment loss (CAL) of 3-4 mm 3. having at least 6 teeth in any arch, not including the third molar 4. systemically healthy Indian patient 5. ready to come for 3-month recall

Exclusion criteria

Exclusion criteria: 1. presence of periapical or pulpal infections on qualifying teeth 2. requiring regular warfarin therapy 3. diagnosed with bile duct obstruction 4. prescribed chemotherapeutic drugs 5. taking any supplement of anti-oxidants for another condition 6. patients averse to taking medications that are not suitable to vegetarians 7. history of hypersensitivity to excipients that are present in CoQ10 dentifrice 8. history of sudden hypoglycaemic episodes 9. oral conditions requiring emergency treatment 10. periodontal conditions indicated for surgical intervention 11. lack of motivation and/or non-compliance to oral hygiene 12. moderate/heavy smoking or any other form of tobacco addiction 13. uncontrolled diabetes mellitus 14. undergoing orthodontic treatment 15. pregnancy and lactation 16. chronic alcohol consumption 17. history of immunocompromised status 18. received scaling, root planing and polishing within 4 months prior to study 19. had periodontal surgery within 6 months prior to study 20. use of systemic or subgingival antimicrobials microbials within 6 months prior to baseline examination 21. ongoing drug therapy that could affect the clinical features of periodontitis or the response to periodontal treatment

Design outcomes

Primary

MeasureTime frame
Clinical Attachment Level.Timepoint: 1.at baseline; 2.at 4 weeks; 3.at 12 weeks

Secondary

MeasureTime frame
Plaque Index, as described by Silness & L e (1964)Timepoint: 1.at baseline; 2.at 4 weeks; 3.at 12 weeks;Gingival index as described by L e & Silness (1963)Timepoint: 1.at baseline; 2.at 4 weeks; 3.at 12 weeks;Bleeding on probing (BOP) as described by Lang et al., (1990)Timepoint: 1.at baseline; 2.at 4 weeks; 3.at 12 weeks;Probing Pocket DepthTimepoint: 1.at baseline; 2.at 4 weeks; 3.at 12 weeks;Relative Attachment Level.Timepoint: 1.at baseline; 2.at 4 weeks; 3.at 12 weeks

Countries

India

Contacts

Public ContactDr Anisha Rani

Uttaranchal Dental and Medical Research Institute

aarongomes@hotmail.com9860597402

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026